Inflammation plays a critical role in cardiometabolic diseases, but traditional risk markers like LDL-C and hs-CRP don’t tell the whole story. Myeloperoxidase (MPO), an enzyme linked to oxidative stress and immune activation, may offer a deeper look into hidden cardiovascular and metabolic risk. In this episode, Dr Marc Penn unpacks the new research examining the association between MPO and the risk for chronic kidney disease (CKD) and  nonalcoholic fatty liver disease (NAFLD) across atherogenic cardiovascular disease (ASCVD) risk groups and what it might mean for prevention and tailored treatment.   This episode will Define MPO (1:30, 5:00) Explain the role of MPO as an inflammatory biomarker and how it differs from traditional cardiometabolic risk markers (2:00) Reveal relationships between MPO, CKD, and NAFLD (7:00) Outline how providers can use MPO to enhance risk stratification and personalize treatment strategies (9:25) Inform listeners on the importance of early detection and prevention of risk factors for cardiometabolic risk (13:00)   The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.   Date: 6/2025 Speaker(s):  Maeson Latsko, PhD; Dr Marc Penn Contributor(s):  Maeson Latsko, PhD; Trisha Winchester, PhD; Kathryn Morales, MS   Additional Resources Ordering information MPO ordering information  Quest Diagnostics Clinical Education Center [Link] References Iakoubova OA, Haji-Sheikhi F, Louie JZ, et al. Association of MPO levels with cardiometabolic disease stratified by atherosclerotic cardiovascular risk and intensity of therapy in a workforce population. Sci Rep. 2025;15(1):12244. Published 2025 Apr 10. doi:10.1038/s41598-025-89373-7